PMID- 34637800
OWN - NLM
STAT- MEDLINE
DCOM- 20211203
LR  - 20211214
IS  - 1879-0631 (Electronic)
IS  - 0024-3205 (Linking)
VI  - 286
DP  - 2021 Dec 1
TI  - Curcuma as an adjuvant in colorectal cancer treatment.
PG  - 120043
LID - S0024-3205(21)01030-4 [pii]
LID - 10.1016/j.lfs.2021.120043 [doi]
AB  - Colorectal cancer (CRC) is the second leading cause of cancer death worldwide and 
      mostly affects men. Around 20% of its incidence is by familiar disposition due to 
      hereditary syndromes. The CRC treatment involves surgery and chemotherapy; 
      however, the side effects of treatments and the fast emergence of drug resistance 
      evidence the necessity to find more effective drugs. Curcumin is the main 
      polyphenol pigment present in Curcuma longa, a plant widely used as healthy food 
      with antioxidant properties. Curcumin has synergistic effects with 
      antineoplastics such as 5-fluorouracil and oxaliplatin, as well anti-inflammatory 
      drugs by inhibiting cyclooxygenase-2 and the Nuclear factor kappa B. Furthermore, 
      curcumin shows anticancer properties by inhibition of the Wnt/beta-catenin, 
      Hedgehog, Notch, and the phosphatidylinositol-3-kinase (PI3K)/Akt and the 
      mammalian target of rapamycin (mTOR) signaling pathways implicated in the 
      progression of CRC. However, the consumption of pure curcumin is less suitable, 
      as the absorption is poor, and the metabolism and excretion are high. 
      Pharmacological formulations and essential oils of the plant improve the curcumin 
      absorption, resulting in therapeutical dosages. Despite the evidence obtained in 
      vitro and in vivo, clinical studies have not yet confirmed the therapeutic 
      potential of curcumin against CRC. Here we reviewed the last scientific 
      information that supports the consumption of curcumin as an adjuvant for CRC 
      therapy.
CI  - Copyright (c) 2021 Elsevier Inc. All rights reserved.
FAU - Villegas, Cecilia
AU  - Villegas C
AD  - Laboratory of Natural Products and Drug Discovery, Department of Basic Sciences, 
      Universidad de La Frontera, Av. Francisco Salazar 01145, Temuco, Chile.
FAU - Perez, Rebeca
AU  - Perez R
AD  - Laboratory of Natural Products and Drug Discovery, Department of Basic Sciences, 
      Universidad de La Frontera, Av. Francisco Salazar 01145, Temuco, Chile.
FAU - Sterner, Olov
AU  - Sterner O
AD  - Division of Organic chemistry, Lund University, Lund, Sweden.
FAU - Gonzalez-Chavarria, Ivan
AU  - Gonzalez-Chavarria I
AD  - Departamento de Fisiopatologia, Facultad de Ciencias Biologicas, Universidad de 
      Concepcion, Concepcion, Chile.
FAU - Paz, Cristian
AU  - Paz C
AD  - Laboratory of Natural Products and Drug Discovery, Department of Basic Sciences, 
      Universidad de La Frontera, Av. Francisco Salazar 01145, Temuco, Chile. 
      Electronic address: cristian.paz@ufrontera.cl.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20211009
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 0 (Adjuvants, Pharmaceutic)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Antioxidants)
RN  - 0 (NF-kappa B)
RN  - 0 (Plant Extracts)
RN  - 0 (Receptors, Notch)
RN  - 0 (beta Catenin)
RN  - 856YO1Z64F (turmeric extract)
RN  - EC 2.7.1.137 (Phosphatidylinositol 3-Kinase)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - IT942ZTH98 (Curcumin)
SB  - IM
MH  - Adjuvants, Pharmaceutic
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology
MH  - Antineoplastic Agents/pharmacology
MH  - Antioxidants/pharmacology
MH  - Cell Line, Tumor
MH  - Chemotherapy, Adjuvant/methods
MH  - Colorectal Neoplasms/*drug therapy/therapy
MH  - Curcuma/metabolism
MH  - Curcumin/metabolism/*pharmacology
MH  - Humans
MH  - NF-kappa B/metabolism
MH  - Phosphatidylinositol 3-Kinase/metabolism
MH  - Plant Extracts
MH  - Receptors, Notch/metabolism
MH  - Signal Transduction/drug effects
MH  - TOR Serine-Threonine Kinases/metabolism
MH  - beta Catenin/metabolism
OTO - NOTNLM
OT  - 5-fluorouracilo
OT  - Chemoprevention
OT  - Chemotherapy
OT  - Clinical trials
OT  - Concomitant therapy
OT  - Curcuma longa
EDAT- 2021/10/13 06:00
MHDA- 2021/12/15 06:00
CRDT- 2021/10/12 20:14
PHST- 2021/08/04 00:00 [received]
PHST- 2021/09/23 00:00 [revised]
PHST- 2021/10/06 00:00 [accepted]
PHST- 2021/10/13 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/10/12 20:14 [entrez]
AID - S0024-3205(21)01030-4 [pii]
AID - 10.1016/j.lfs.2021.120043 [doi]
PST - ppublish
SO  - Life Sci. 2021 Dec 1;286:120043. doi: 10.1016/j.lfs.2021.120043. Epub 2021 Oct 9.